# US 2021/0228505 A1 · Method of treating major depressive disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228505 A1
- Document ID: US20210228505A1
- Status: Published application
- Kind: A1
- Application number: 17/229,623
- Filed: 2021-04-13
- Published: 2021-07-29
- Earliest claimed: 2018-10-05
- Assignees: Clexio Biosciences Ltd.
- Applicants: Clexio Biosciences Ltd.
- Inventors: Elena Kagan; Gina Pastino
- Web page: https://patentgrep.com/patent/US20210228505A1

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1611: {Inorganic compounds}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/167: {with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface (with further drug-free outer coating A61K9/5073)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/15: Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/381: having five-membered rings
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method for safe and efficacious administration of esketamine.

## Claims

### Claim 1

A method of treating major depressive disorder (MDD) in a human patient in need thereof comprising orally administering once daily to said patient for at least 28 days, an oral dosage form comprising 40 mg of esketamine.

### Claim 2 (depends on 1)

The method of claim 1, further comprising the administration of an antidepressant selected from the group consisting of fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, desvenlafaxine, duloxetine, and fluvoxamine.

### Claim 3 (depends on 1)

The method of claim 1, wherein the esketamine is esketamine hydrochloride.

### Claim 4 (depends on 1)

The method of claim 1, wherein the treatment comprises a reduction in the symptoms of major depressive disorder (MDD).

### Claim 5 (depends on 4)

The method of claim 4, wherein the reduction in the symptoms of major depressive disorder (MDD) is measured by a reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) score as compared to baseline after at least 28 days of administration or after at least 14 days of administration of the oral dosage form of esketamine.

### Claim 6 (depends on 4)

The method of claim 4, wherein the reduction in the symptoms of major depressive disorder (MDD) is measured by a reduction in the Symptoms of Depression Questionnaire (SDQ) score as compared to baseline after at least 28 days of administration of the oral dosage form of esketamine.

### Claim 7 (depends on 4)

The method of claim 4, wherein the reduction in the symptoms of major depressive disorder (MDD) is measured by a reduction in the Sheehan Disability Scale (SDS) as compared to baseline after at least 28 days of administration of the oral dosage form of esketamine.

### Claim 8 (depends on 4)

The method of claim 4, wherein the reduction in the symptoms of major depressive disorder (MDD) is measured by a reduction in the Clinical Global Impression-Severity (CGI-S) score as compared to baseline after at least 28 days of administration of the oral dosage form of esketamine.

### Claim 9 (depends on 4)

The method of claim 4, wherein the reduction in the symptoms of major depressive disorder (MDD) is in comparison to placebo and is after at least 28 days of administration of the oral dosage form of esketamine.

### Claim 10 (depends on 1)

The method of claim 1, wherein prior to the administration, the human patient has not responded to adequate doses and treatment durations of antidepressants other than ketamine or esketamine.

### Claim 11 (depends on 1)

The method of claim 1, wherein prior to the administration, the human patient has failed to demonstrate an improvement of up to 25% in the Montgomery-Åsberg Depression Rating Scale (MADRS) score after adequate doses and treatment durations of antidepressants other than ketamine or esketamine.

### Claim 12 (depends on 1)

The method of claim 1, wherein prior to the administration, the human patient has failed to demonstrate an improvement of up to 50% in the Montgomery-Åsberg Depression Rating Scale (MADRS) score after adequate doses and treatment durations of antidepressants other than ketamine or esketamine.

### Claim 13 (depends on 1)

The method of claim 1, wherein prior to the administration, the human patient has demonstrated an improvement of between 25 and 50% in the Montgomery-Åsberg Depression Rating Scale (MADRS) score after adequate doses and treatment durations of antidepressants other than ketamine or esketamine.

### Claim 14 (depends on 1)

The method of claim 1, wherein the administration of the oral dosage form is at night.

### Claim 15 (depends on 1)

The method of claim 1, wherein the administration of the oral dosage form is before the human patient goes to sleep.

### Claim 16 (depends on 1)

The method of claim 1, wherein the oral dosage form is self-administered by the human patient.

### Claim 17 (depends on 16)

The method of claim 16, wherein the self-administration is in the human patient's own home.

### Claim 18 (depends on 1)

The method of claim 1, wherein following the administration of the oral dosage form, the patient is restricted from driving for no more than eight hours.

### Claim 19 (depends on 1)

The method of claim 1, wherein following the administration of the oral dosage form, the patient is restricted from driving until the morning following the administration.

### Claim 20

A method of treating major depressive disorder (MDD) in a human patient in need thereof wherein the human patient orally self-administers once daily for at least 28 days an oral dosage form comprising 40 mg of esketamine.
